Adynxx (FRA:HL1C) Institutional Ownership : 13.65% (As of Jun. 02, 2024)

View and export this data going back to 1998. Start your Free Trial

What is Adynxx Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Adynxx's institutional ownership is 13.65%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Adynxx's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Adynxx's Float Percentage Of Total Shares Outstanding is 67.32%.

Adynxx Institutional Ownership Historical Data

The historical data trend for Adynxx's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Institutional Ownership Chart

Adynxx Historical Data

The historical data trend for Adynxx can be seen below:

	2018-06-30	2018-07-31	2018-08-31	2018-09-30	2018-10-31	2018-11-30	2018-12-31	2019-01-31	2019-02-28	2019-04-30
Institutional Ownership	19.14	17.97	17.97	22.30	22.30	22.30	13.96	14.30	14.30	13.65

Adynxx Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Adynxx (FRA:HL1C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (FRA:HL1C) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Pine Street, Suite 500, San Francisco, CA, USA, 94111

Website

http://www.adynxx.com

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Adynxx (FRA:HL1C) Headlines

No Headlines